Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month
Yıl: 2022 Cilt: 47 Sayı: 1 Sayfa Aralığı: 9 - 18 Metin Dili: İngilizce DOI: 10.1515/tjb-2021-0200 İndeks Tarihi: 17-05-2023
Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month
Öz: Background: There is a knowledge gap about the characteristics of neutralizing antibody (NAb) response in patients who recovered COVID-19. In this study, it is aimed to elucidate the factors affecting the presence and titers of antibodies up to 30-days after onset. Material and methods: A total of 129 laboratory-confirmed COVID-19 patients were enrolled. Clinical data were obtained retrospectively. SARS-CoV-2 specific NAb, IgM, and IgG antibody responses were analyzed. Results: SARS-CoV-2 specific NAb, IgM and IgG, were detected at the time of hospital discharge in 60.5%, 30.2%, and 51.9% of the patients, respectively. The median time for obtaining serum samples for antibody tests after symptoms’ onset was 11 days. The median titer of neutralizing antibody (SN50) was significantly higher in severe patients (25 vs. 7.5, p=0.009). Of the 23 severe patients, 52.2% (n=12) had higher NAb titers (i.e., SN50≥1:25) when compared to that in non-severe patients (OR=2.89; 95%CI=1.15–7.28, p=0.021), yet, the potential effect of follow-up time on NAb status and titers could not be ruled out. Conclusions: The presence of antibody response is not the only determinative factor for recovery. The presence and higher titers of NAb were detected more in severe patients than their non-severe counterparts. Survival analysis suggested that this difference could at least be partially explained by the length of follow-up through antibody testing (at discharge) after symptoms’ onset.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Ota M. Will we see protection or reinfection in COVID-19? Nat Rev Immunol 2020;20:351.
- 2. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020;20:565–574.
- 3. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications; 2020, https://doi.org/10. 1101/2020.03.30.20047365.
- 4. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol 2020;73:366–9.
- 5. Okba NM, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv; 2020.
- 6. World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) Ehen COVID-19 Disease is Suspected: Interim Guidance, 13 March 2020. World Health Organization; 2020.
- 7. Health NIo. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019. (COVID-19) Treatment Guidelines [cited 2020 29.05]; 2020.
- 8. Taylor MJ, Perrais D, and Merrifield CJ. A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis. PLoS Biol 2011;9:e1000604.
- 9. Hanifehnezhad A, Kehribar EŞ, Öztop S, Sheraz A, Kasırga S, Ergünay K, et al. Characterization of local SARS-CoV-2 isolatesand pathogenicity in IFNAR–/-mice. Heliyon 2020;6:e05116.
- 10. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020:1–4.
- 11. Wang J, Chen C, Li Q, Cai P, Wang Z, and Wang L. COVID-19 confirmed patients with negative antibodies results. BMC Infect Dis 2020;20:1–4.
- 12. Leung H. Can you be Re-infected after recovering from coronavirus? Here’s what we know about COVID-19 immunity, 2020. Available from: https://time.com/5810454/coronavirusimmunity- reinfection/.
- 13. Yuchun N, Guangwen W, Xuanling S, Hong Z, Yan Q, Zhongping H, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004;190:1119.
- 14. Kalkan M, Koç M, Çetin N, Karaaslan E, Okay G, Durdu B, et al. Discordance between serum neutralizing antibody titers and the recovery from COVID-19. J. Immunol. 2020;205:2719–25.
- 15. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020;183:996–1012.
- 16. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 2020;71:2027–34.
- 17. Peiris JSM, Chu C-M, Cheng VC-C, Chan K, Hung I, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767–72.
- 18. ChenW, Zhang J, Qin X,WangW, XuM,Wang L-F, et al. SARS-CoV-2 neutralizing antibody levels are correlated with the severity of COVID-19 pneumonia. Biomed Pharmacother 2020;130:110629.
- 19. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:2255–8.
| APA | Bastug A, Bodur H (2022). Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. , 9 - 18. 10.1515/tjb-2021-0200 |
| Chicago | Bastug Aliye,Bodur Hurrem Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. (2022): 9 - 18. 10.1515/tjb-2021-0200 |
| MLA | Bastug Aliye,Bodur Hurrem Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. , 2022, ss.9 - 18. 10.1515/tjb-2021-0200 |
| AMA | Bastug A,Bodur H Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. . 2022; 9 - 18. 10.1515/tjb-2021-0200 |
| Vancouver | Bastug A,Bodur H Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. . 2022; 9 - 18. 10.1515/tjb-2021-0200 |
| IEEE | Bastug A,Bodur H "Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month." , ss.9 - 18, 2022. 10.1515/tjb-2021-0200 |
| ISNAD | Bastug, Aliye - Bodur, Hurrem. "Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month". (2022), 9-18. https://doi.org/10.1515/tjb-2021-0200 |
| APA | Bastug A, Bodur H (2022). Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. Türk Biyokimya Dergisi, 47(1), 9 - 18. 10.1515/tjb-2021-0200 |
| Chicago | Bastug Aliye,Bodur Hurrem Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. Türk Biyokimya Dergisi 47, no.1 (2022): 9 - 18. 10.1515/tjb-2021-0200 |
| MLA | Bastug Aliye,Bodur Hurrem Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. Türk Biyokimya Dergisi, vol.47, no.1, 2022, ss.9 - 18. 10.1515/tjb-2021-0200 |
| AMA | Bastug A,Bodur H Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. Türk Biyokimya Dergisi. 2022; 47(1): 9 - 18. 10.1515/tjb-2021-0200 |
| Vancouver | Bastug A,Bodur H Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month. Türk Biyokimya Dergisi. 2022; 47(1): 9 - 18. 10.1515/tjb-2021-0200 |
| IEEE | Bastug A,Bodur H "Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month." Türk Biyokimya Dergisi, 47, ss.9 - 18, 2022. 10.1515/tjb-2021-0200 |
| ISNAD | Bastug, Aliye - Bodur, Hurrem. "Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month". Türk Biyokimya Dergisi 47/1 (2022), 9-18. https://doi.org/10.1515/tjb-2021-0200 |
